Financial Markets
Real Estate
Local listed Company
Overseas-listed Company
Foreign Company
Industrial Parks

Financial Market
 Search News  Or
Kangmei Pharma to raise RMB 3.5 bln via rights issue

Dec. 28, 2010 (China Knowledge) - Kangmei Pharmaceutical Co Ltd<600518>, one of the top ten listed traditional Chinese medicine makers, on Dec. 27 said it has received approval from the China Securities Regulatory Commission to raise up to RMB 3.5 billion through a rights issue today.

In a statement filed with the Shanghai Stock Exchange, the company will issue three new shares for every ten existing shares, and around 508 million new shares are expected to be sold at a price of RMB 6.88 apiece.

The firm said the rights issue will be completed on Jan. 6, 2011 and its shares will resume trading on the same day.

GF Securities Co Ltd<000776> has been assigned as the lead underwriter for the rights issue, sources reported.

Copyright © "2013"

Send feedback or comments to:

For more news, financial weekly reports, business guides to China, Market Research Reports and other premium information, subscribe to China Knowledge today

To access our page on Bloomberg, type CKFI (GO)

 Our Professional Services
 News Archive
About Us | CSR | Media Center | E-Newsletter | E-Store | Contact Us | Feedback | Sitemap | Privacy Policy | Terms of Use  

           Copyright © 2014 China Knowledge Online. All Rights Reserved